Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas

European Journal of Surgical Oncology

Volumn 35, Issue 6, 2009, Pages 605-610

  Pine, J K ^b   Fusai, K G ^a   Young, R ^b   Sharma, D ^a   Davidson, B R ^a   Menon, K V ^b   Rahman, S H ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

C reactive protein (CRP); Ductal adenocarcinoma of the pancreas; Prognosis; Survival

Indexed keywords

BILIRUBIN; C REACTIVE PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BILE DUCT OBSTRUCTION; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 67349133105     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2008.12.002     Document Type: Article

References (33)

1. Office of National Statistics. Cancer survival: cancer survival trends by period of diagnosis and sex age-standardised relative survival at one and five years, and average increase in relative survival between successive five-year periods of diagnosis, 1971-1990; 2005.
2. Richter A., Niedergethmann M., Sturm J.W., Lorenz D., Post S., and Trede M. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg 27 (2003) 324-329
3. Griffanti-Bartoli F., Arnone G.B., Ceppa P., Ravera G., Carabetta S., and Civalleri D. Malignant tumours in the head of the pancreas and the periampullary region. Diagnostic and prognostic aspects. Anticancer Res 14 (1994) 657-666
4. Hermanek P. Pathology and biology of pancreatic ductal adenocarcinoma. Langenbecks Arch Surg 383 (1998) 116-120
5. Ozaki H., Hiraoka T., Mizumoto R., et al. The prognostic significance of lymph node metastases and intrapancreatic perineural invasion in pancreatic cancer after curative resection. Surg Today 29 (1999) 16-22
6. Greer R.J., and Brennan M.F. Resection of pancreatic adenocarcinoma: prognostic indicators for survival. Am J Surg 195 (1993) 68-73
7. Benassi G., Mastroilli M., Quarto G., et al. Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas. J Surg Oncol 73 (2000) 212-218
8. Yeo C.J., Cameron J.L., Sohn T.A., et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 226 (1997) 248-260
9. Fortner J.G., Klimstra D.S., Senie R.T., and Maclean B.J. Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. Ann Surg 223 (1996) 147-153
10. Yeo C.J., Cameron J.L., Lillemoe K.D., et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomised controlled trial evaluating survival, morbidity and mortality. Ann Surg 236 (2002) 355-368
11. Balkwill F., and Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 357 (2001) 539-545
12. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
13. Jamieson N.B., Glen P., McMillan D.C., et al. Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. Br J Cancer 92 (2005) 21-23
14. Tingstedt B., Johansson P., Andersson B., and Andersson R. Predictive factors in pancreatic ductal adenocarcinoma: role of inflammatory response. Scand J Gastroenterol 42 (2007) 754-759
15. Verbeke C.S., Leitch D., Menon K.V., McMahon M.J., Guillou P.J., and Anthoney A. Redefining the R1 resection in pancreatic cancer. Br J Surg 93 (2006) 1232-1237
16. Glen P., Jamieson N.B., McMillan D.C., Carter R., Imrie C.W., and McKay C.J. Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology 6 (2006) 450-453
17. Kalser M.H., Barkin J., and MacIntyre J.M. Pancreatic cancer. Assessment of prognosis by clinical presentation. Cancer 56 (1985) 397-402
18. Sezgin C., Karabulut B., Uslu R., et al. Gemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic caner and prognostic factors. Scand J Gastroenterol 40 (2005) 1486-1492
19. Park J.K., Yoon Y.B., Kim Y.T., Ryu J.K., Yoon W.J., and Lee S.H. Survival and prognostic factors of unresectable pancreatic cancer. J Clin Gastroenterol 42 (2008) 86-91
20. Falconer J.S., Fearon K.C.H., Ross J.A., et al. Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 75 (1995) 2077-2082
21. Engelken F.J.F., Bettschart V., Rahman M.Q., Parks R.W., and Garden O.J. Prognostic factors in the palliation of pancreatic cancer. Eur J Surg Oncol 29 (2003) 368-373
22. Fearon K.C., Voss A.C., and Hustead D.S. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 83 (2006) 1345-1350
23. Ueno H., Okada S., Okusaka T., and Ikeda M. Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 59 (2000) 296-301
24. O'Gorman P., McMillan D.C., and McArdle C.S. Prognostic factors in advanced gastrointestinal cancer patients with weight loss. Nutr Cancer 37 (2000) 36-40
25. Jagannath P., Dhir V., Shrikhande S., Shah R.C., Mullerpatan P., and Mohandas K.M. Effect of preoperative biliary stenting on immediate outcome after pancreaticoduodenectomy. Br J Surg 92 (2005) 356-361
26. Padillo F.J., Muntane J., Montero J.L., et al. Effect of internal biliary drainage on plasma levels of endotoxin, cytokines, and C-reactive protein in patients with obstructive jaundice. World J Surg 26 (2002) 1328-1332
27. Neoptolemos J.P., Stocken D.D., Friess H., et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. European Study Group for Pancreatic Cancer. N Engl J Med 350 (2004) 1200-1210
28. Miki C., Konishi N., Ojima E., Hatada T., Inous Y., and Kusunoki M. C-reactive protein as a prognostic variable that reflects uncontrolled up-regulation of the IL-1-IL-6 network system in colorectal carcinoma. Dig Dis Sci 49 (2004) 970-976
29. Fearon K.C., Barber M.D., Falconer J.S., McMillan D.C., Ross J.A., and Preston T. Pancreatic cancer as a model: inflammatory mediators, acute-phase response, and cancer cachexia. World J Surg 23 (1999) 584-588
30. Nakachi K., Furuse J., Ishii H., Suzuki E., and Yoshino M. Prognostic factors in gemcitabine refractory advanced pancreatic cancer patients. Jpn J Clin Oncol 37 (2007) 114-120
31. McMillan D.C., Canna K., and McArdle C.S. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 90 (2003) 215-219
32. Yau M., Kargman S., Lam E.C., et al. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res 63 (2003) 586-592
33. Mukherjee D., Nissen S.E., and Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. J Am Med Assoc 286 (2001) 954-959